ASKA Pharmaceutical Holdings Co., Ltd. (JP:4886)
:4886
4886 Stock Chart & Stats
¥2038.00
-¥23.00(-1.13%)
At close: 4:00 PM EST
¥2038.00
-¥23.00(-1.13%)
Day’s Range― - ―
52-Week Range¥1,920.00 - ¥2,942.00
Previous CloseN/A
Volume48.10K
Average Volume (3M)49.10K
Market Cap
¥69.27B
Enterprise Value¥81.94B
Total Cash (Recent Filing)¥7.23B
Total Debt (Recent Filing)¥13.77B
Price to Earnings (P/E)8.6
Beta0.55
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.52%
Share Statistics
EPS (TTM)59.10
Shares Outstanding28,763,199
10 Day Avg. Volume37,820
30 Day Avg. Volume49,100
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)1.00
Price to Sales (P/S)1.02
P/FCF Ratio-137.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)197.8
Revenue Forecast (FY)¥71.06B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthMulti-year revenue growth in a specialty pharmaceuticals franchise indicates steady demand and effective product lifecycle management. For a company focused on gynecology and specialty prescriptions in Japan, durable top-line expansion supports reinvestment in R&D and predictable recurring revenues from prescriptions.
High Gross MarginsSustained gross margins near 48.5% reflect strong pricing power and a high-value product mix typical of specialty drugs. Robust gross margins provide a structural cushion against COGS variability, enabling continued investment in R&D, manufacturing quality, and commercialization without immediate margin dilution.
Improved Balance SheetSignificant reduction in leverage and a strong equity ratio enhance financial flexibility. Lower debt service requirements improve resilience to reimbursement or product-cycle shocks and make it easier to fund R&D, lifecycle management, or selective M&A from internal resources or conservative financing.
Bears Say
Declining Net MarginsA material drop in net margin suggests rising operating costs or pricing pressure that is eroding bottom-line profitability. If this trend persists, it will limit internally generated funds for R&D, dividends, and strategic investments, forcing tougher cost management or margin recovery actions.
Weaker Free Cash FlowVolatile and reduced free cash flow despite positive operating cash flow ratios signals inconsistent cash conversion. Weaker FCF constrains the firm’s ability to sustainably fund R&D, support dividends, or pursue acquisitions without drawing on reserves or increasing leverage.
Domestic Concentration RiskHeavy reliance on the Japanese prescription market and the women’s health niche concentrates regulatory, reimbursement, and demographic exposure. Limited geographic diversification reduces alternative growth vectors and increases sensitivity to country-specific policy or pricing changes.
ASKA Pharmaceutical Holdings Co., Ltd. News
4886 FAQ
What was ASKA Pharmaceutical Holdings Co., Ltd.’s price range in the past 12 months?
ASKA Pharmaceutical Holdings Co., Ltd. lowest stock price was ¥1920.00 and its highest was ¥2942.00 in the past 12 months.
What is ASKA Pharmaceutical Holdings Co., Ltd.’s market cap?
ASKA Pharmaceutical Holdings Co., Ltd.’s market cap is ¥69.27B.
When is ASKA Pharmaceutical Holdings Co., Ltd.’s upcoming earnings report date?
ASKA Pharmaceutical Holdings Co., Ltd.’s upcoming earnings report date is May 07, 2026 which is in 31 days.
How were ASKA Pharmaceutical Holdings Co., Ltd.’s earnings last quarter?
ASKA Pharmaceutical Holdings Co., Ltd. released its earnings results on Feb 02, 2026. The company reported ¥59.1 earnings per share for the quarter, beating the consensus estimate of N/A by ¥59.1.
Is ASKA Pharmaceutical Holdings Co., Ltd. overvalued?
According to Wall Street analysts ASKA Pharmaceutical Holdings Co., Ltd.’s price is currently Overvalued.
Does ASKA Pharmaceutical Holdings Co., Ltd. pay dividends?
ASKA Pharmaceutical Holdings Co., Ltd. pays a Semiannually dividend of ¥28 which represents an annual dividend yield of 2.52%. See more information on ASKA Pharmaceutical Holdings Co., Ltd. dividends here
What is ASKA Pharmaceutical Holdings Co., Ltd.’s EPS estimate?
ASKA Pharmaceutical Holdings Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ASKA Pharmaceutical Holdings Co., Ltd. have?
ASKA Pharmaceutical Holdings Co., Ltd. has 28,763,199 shares outstanding.
What happened to ASKA Pharmaceutical Holdings Co., Ltd.’s price movement after its last earnings report?
ASKA Pharmaceutical Holdings Co., Ltd. reported an EPS of ¥59.1 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -7.046%.
Which hedge fund is a major shareholder of ASKA Pharmaceutical Holdings Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4886
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co.,Ltd., through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan. The company researches, develops, manufactures, and markets pharmaceutical products in the areas of endocrinology, obstetrics and gynecology, and urology; and manufactures, sells, imports, and exports veterinary medicines, veterinary medical devices, feed and feed additives, reagents, agrochemicals, industrial chemicals, hygiene products, and food products and their raw materials. It is also involved in the clinical examination and biological testing activities; and offers medical devices. The company was founded in 1920 and is headquartered in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Fuji Pharma Co., Ltd.
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
Daito Pharmaceutical Co., Ltd.
―
Options Prices
Currently, No data available
---